Olanzapine + Fluoxetine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Depressive phase of bipolar disorder
Adult: Each cap contains olanzapine 6 mg and fluoxetine 25 mg: 1 cap once daily at night.
Child: 10-17 yr Each cap contains olanzapine 3 mg and fluoxetine 25 mg: 1 cap once daily at night.

Oral
Adjunct in treatment-resistant depression
Adult: Each cap contains olanzapine 6 mg and fluoxetine 25 mg: 1 cap once daily at night.
Renal Impairment
No dosage adjustment needed.
Hepatic Impairment
Initially, olanzapine 3 mg and fluoxetine 25 mg increased to olanzapine 6 mg and fluoxetine 25 mg.
Chống chỉ định
Not to be used w/ or w/in 14 days of discontinuing treatment w/ MAOIs (e.g. linezolid, methylene blue). Concomitant MAOIs or w/in 5 wk of discontinuing treatment w/ olanzapine and fluoxetine. Concomitant use w/ QT prolonging drugs (e.g. pimozide, thioridazine). Childn <10 yr.
Thận trọng
Elderly w/ dementia-related psychosis. Increased risk of suicidal thinking and behaviour in childn, adolescents and young adults. Patients w/ congenital long QT syndrome. Hepatic impairment. Pregnancy and lactation.
Phản ứng phụ
Hyperglycaemia, hyperlipidaemia, increased wt, rash and/or urticaria, bronchospasm, angioedema, mania activation/hypomania, tardive dyskinesia, orthostatic hypotension, neutropenia, agranulocytosis, leukopenia, dysphagia, seizures, abnormal bleeding, hyponatremia, body temp dysregulation, hyperprolactinaemia.
Potentially Fatal: Serotonin and neuroleptic malignant syndrome; QT prolongation including torsade de pointes.
Thông tin tư vấn bệnh nhân
May impair ability to drive or operate machinery.
MonitoringParameters
Monitor worsening of suicidal thoughts and behaviour. Monitor ECG periodically and fasting blood lipid testing prior and during treatment.
Quá liều
Symptoms: Coma, loss of consciousness, convulsions, ataxia, confusion, dysarthria, somnolence, lethargy, agitation, essential tremor, arrhythmias, acute psychosis, aggression, HTN, hypotension. Management: Establish and maintain airway for adequate ventilation (e.g. intubation). Monitor CV function immediately w/ continuous ECG monitoring to detect possible arrhythmias.
Tương tác
Increased risk of bleeding w/ NSAIDs, warfarin and aspirin. May potentiate orthostatic hypotension w/ benzodiazepines. May increase serum levels and toxicity of phenytoin and carbamazepine. May enhance the effects of certain antihypertensives. Olanzapine may antagonise the effects of levodopa and dopamine agonists. May increase serum levels of clozapine and haloperidol. Fluvoxamine may increase the serum levels of olanzapine.
Potentially Fatal: Concomitant use w/ MAOI (e.g. methylene blue, linezolid) may cause serotonin syndrome. Increased risk of QT prolongation w/ QT prolonging drugs (e.g. pimozide and thioridazine).
Food Interaction
Concomitant use w/ alcohol may potentiate sedation and orthostatic hypotension.
Tác dụng
Description: Fluoxetine is a potent and predominantly selective inhibitor of serotonin (monoamine transmitter) which has no affinity for adrenoceptors or histamine, GABA-B, or muscarinic receptors. It prevents the reuptake of serotonin, which potentiates its action in the brain. Olanzapine is an atypical antipsychotic w/ affinity for serotonin 5-HT2A/2C, dopamine, muscarinic M1-M5, histamine H1 and adrenergic α1 receptors.
Pharmacokinetics:
Absorption: Fluoxetine is readily absorbed from the GI tract. Olanzapine is well absorbed from the GI tract. Bioavailability: Fluoxetine: Approx 60-80%. Time to peak plasma concentration: Fluoxetine: Approx 6-8 hr. Olanzapine: Approx 5-8 hr.
Distribution: Fluoxetine crosses the blood-brain barrier. Olanzapine crosses the placenta and highly lipophilic. Plasma protein binding: Fluoxetine: Approx 95%. Olanzapine: Approx 93%.
Metabolism: Both are extensively metabolised in the liver. Fluoxetine undergoes hepatic demethylation via CYP2D6 isoenzyme to its primary active metabolite norfluoxetine. Olanzapine undergoes direct glucuronidation and oxidation via CYP1A2 isoenzyme and to a lesser extent via CYP2D6 isoenzyme to its metabolites 10-N-glucuronide and 4'-N-desmethyl.
Excretion: Fluoxetine: Mainly via urine. Elimination half-life: Approx 1-3 days (acute use); 4-6 days (long-term use). Olanzapine: Via urine (approx 57%, mainly as metabolites); via faeces (approx 30%). Elimination half-life: Approx 30-38 hr.
Bảo quản
Store at 25°C.
Phân loại MIMS
References
Buckingham R (ed). Fluoxetine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 16/09/2013.

Buckingham R (ed). Olanzapine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 16/09/2013.

Joint Formulary Committee. Fluoxetine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 16/09/2013.

Joint Formulary Committee. Olanzapine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 16/09/2013.

McEvoy GK, Snow EK, Miller J et al (eds). Fluoxetine Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 16/09/2013.

McEvoy GK, Snow EK, Miller J et al (eds). Olanzapine, Olanzapine Pamoate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 16/09/2013.

Symbyax (Eli Lilly and Company). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 16/09/2013.

Symbyax (Olanzapine and Fluoxetine HCL) Capsules. U.S. FDA. https://www.fda.gov/. Accessed 16/09/2013.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Olanzapine + Fluoxetine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in